May will see US FDA decisions for Apellis, Heron and Bristol Myers Squibb, while Provention Bio is set for a panel meeting.
The company reveals that it will test a low dose of sotorasib, a move apparently requested by the US FDA.
A pivotal win puts nirsevimab on track to be filed next year, but the reimbursement hurdle looms.
Many corporate-backed funds remain enthusiastic venture investors, but some might be hitting the brakes.
Meanwhile, Ocugen hopes that Covaxin's India data will be enough for US approval.